20 hrs ago
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): What To Know About Obesity
The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc.
Mon May 13, 2013
Arena Pharmaceuticals, Inc. (ARNA): You Need To See These 5 Points
A sharp drop in Arena Pharmaceuticals followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application in the EU.
Sat May 11, 2013
The Motley Fool
Deal Discussions Distract From Disappointing Obesity Drug Sales
In this video, health-care analyst David Williamson looks at Vivus ' first-quarter results and breaks it down into key takeaways for investors in both Vivus and its competitor Arena .
Fri May 10, 2013
Belviq's Sales Will Disappoint: Demographics Matter
Arena Pharmaceuticals has now received its long anticipated scheduling for Belviq from the DEA , and its fate in Europe , at least in the short-term, is a known for investors.
Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com . A replay of the presentation will be available for 30 days following the event.
Monterey County Herald
Weight-loss pill cleared for sales
Arena Pharmaceuticals' Belviq, the weight-loss pill approved in June by the Food and Drug Administration, was cleared to start sales next month after a separate review found the drug's abuse potential to be low.
Wed May 08, 2013
Arena Pharmaceuticals, Inc. Pockets $65 Million From Partner Eisai Inc. After Belviq Approval
The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal Register.
Free Research Reports on AMRI, ARNA, MKTG and SCTY Issued by the Paragon Report
As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.
Tue May 07, 2013
Arena Pharmaceuticals, Inc. (ARNA): The Mind-Blowing Data You Missed
The number of bullish hedge fund positions inched up by 3 lately. At the moment, there are dozens of gauges shareholders can use to track stocks.
Arena And Vivus Weaken On Poor Obesity Drug Prospects In Europe
Responding to news that the company would withdraw its MAA for Belviq from the EMA, shares of Arena Pharmaceuticals tanked by 9.2% last Friday as investors questioned whether obesity drugs had a future in the EU market.
Mon May 06, 2013
Sun May 05, 2013
The Motley Fool
Are Obesity Drugs a Lost Cause in Europe?
Arena Pharmaceuticals had a rough quarter, but the results don't really matter. The company is waiting on DEA scheduling before it can start selling its obesity drug, Belviq.
Sat May 04, 2013
Perfect Trade Setups, How to Play MU, NWSA, ARNA and NTAP
Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand how it plays out into future stock price.
Fri May 03, 2013
Arena shares plunge after disappointing 1Q results Arena...
Arena Pharmaceuticals Inc. said Thursday that its loss narrowed in the first quarter, though company executives said they are still waiting for a federal decision on the status of the weight loss drug Belviq.
On The Fly: Pre-market Movers
Check below for free stories on AIG;ARNA;PKT;DDD;SPLS;DCTH;YRCW;INVN;WTW;BBRY;SKUL the last two weeks.
Mid-Day Market Update: Thoratec Dips On Downbeat Profit, InvenSense Rises
Midway through trading Friday, the Dow traded up 1.04 percent to 14,985.73 while the NASDAQ surged 1.29 percent to 3,383.74. The S&P also rose, gaining 1.13 percent to 1,615.66. LinkedIn posted its first-quarter earnings at $22.6 million, or $0.20 per share, versus $5 million, or $0.04 per share, in the year-ago period.
Arena Pharmaceuticals, Inc. Provides Corporate Update and Reports...
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN DIEGO, May 2, 2013 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc.
Thu May 02, 2013
Arena Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Welcome, ladies and gentlemen and welcome to the Arena Pharmaceuticals first quarter 2013 financial results call.
Arena Withdrawing Obesity Drug Regulatory Application in Europe
Arena Pharmaceuticals Inc. , the maker of the weight-loss drug Belviq, said it is withdrawing its application to gain regulatory approval in Europe for the obesity medicine.
Wed May 01, 2013
Pfizer Inc. (PFE), Eli Lilly & Co. (LLY) & Other Names To Know: A Full Breakdown
Investing in biotech companies can be intimidating, especially for investors without a science background.